BCR::ABL1 PCR
Clinical Background:
Used for monitoring chronic myeloid leukaemia as per national and international guidelines. CML arises from the fusion of the BCR and ABL1 gene due to a translocation between chromosomes 9 and 22. ...
Used for monitoring chronic myeloid leukaemia as per national and international guidelines. CML arises from the fusion of the BCR and ABL1 gene due to a translocation between chromosomes 9 and 22. Quantitative PCR (qPCR) is a method used to determine copy numbers of ABL1 and BCR::ABL1. Results are reported as a ratio between BCR::ABL1 and ABL1.
Test Details
-
Discipline:
NEHODS
NEHODS
-
Specimen Container Adult:
EDTA blood
EDTA blood
-
Specimen Container Paediatric:
EDTA blood
EDTA blood
-
Minimum Volume Adult:
5 mL
5 mL
-
Minimum Volume Paediatric:
5 mL
5 mL
-
Special Requirement:
Please complete NEHODS request form
Please complete NEHODS request form
-
Sample Stability:
Needs to be received within 24hrs of sampling
Needs to be received within 24hrs of sampling
-
Transport Requirements:
Samples should be sent to laboratory immediately.
Samples should be sent to laboratory immediately.
-
Freq Analysis:
Daily
Daily
-
Add On Test:
Can be added to any genetics sample where appropriate material has been stored
Can be added to any genetics sample where appropriate material has been stored
-
Quality Assurance:
UK NEQASLI
UK NEQASLI
-
Interpretation:
By genetics clinical scientist
By genetics clinical scientist
-
Reference Ranges:
N/A
N/A
-
Factors Affecting Result:
Quality and size of sample
Quality and size of sample
-
Referenced Documents:
N/A
N/A
-
Other Info:
Samples should be sent at timelines according to BSH and ELN guidelines. A baseline PCR will be performed for all new cases of CML. This assay only picks up the major e13a2 and/or e14a2 breakpoint....
Read MoreSamples should be sent at timelines according to BSH and ELN guidelines. A baseline PCR will be performed for all new cases of CML. This assay only picks up the major e13a2 and/or e14a2 breakpoint. If the major breakpoint is not detected samples will be referred to another laboratory to confirm the breakpoint and to deliver ongoing monitoring. The major breakpoint is reported on the international scale by use of a laboratory specific conversion factor. ABL1 kinase domain mutations are a cause of tyrosine kinase resistance in patients with CML. ABL1 kinase domain mutation resistance can be added on and is performed by NGS by the South East Haematological Malignancy Diagnostic Service (SE HMDS).